<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE ichicsr SYSTEM "http://eudravigilance.ema.europa.eu/dtd/icsr21xml.dtd">
<ichicsr lang="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>1.0</messageformatrelease>
		<messagenumb>0001</messagenumb>
		<messagesenderidentifier>MLMSERVICE</messagesenderidentifier>
		<messagereceiveridentifier>EVTESTWT</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20150629134236</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-35</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150410</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150407</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150407</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist />
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-35</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm />
		<primarysource>
			<reportertitle />
			<reportergivename>Daisuke</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Takeuchi</reporterfamilyname>
			<reporterorganization>Tsuruga Onsen Hospital</reporterorganization>
			<reporterdepartment>Psychiatry</reporterdepartment>
			<reporterstreet />
			<reportercity />
			<reporterstate>Fukui</reporterstate>
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Daisuke Takeuchi, et al. Two Cases of Chronic Somatic Pain Successfully Treated with Duloxetine. Japanese Journal of Psychiatric Treatment. 2015;30 (3):415-419</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>UNKNOWN</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>80</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>2</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures>MPQ (MacGill Pain Questionnaire) (middle AugX+1): 32 pointsMPQ (MacGill Pain Questionnaire): 9 pointsMPQ (MacGill Pain Questionnaire) (early DecX+1): 21 pointsMPQ (MacGill Pain Questionnaire) (FebX+2): 11 points</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10012378</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>drug-induced ileus</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10021328</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Chest X-ray</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Chest X-ray</testname>
				<testresult>showed no fracture</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Haematology test</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Laboratory test</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Thyroid function test</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Electrocardiogram</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Computerised tomogram head</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Electroencephalogram</testname>
				<testresult>normal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Ham test</testname>
				<testresult>6 points</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Ham test</testname>
				<testresult>2 points</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Ham test</testname>
				<testresult>3 points</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Ham test</testname>
				<testresult>2 points</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ACETAMINOPHEN</medicinalproduct>
				<obtaindrugcountry />
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb>600</drugstructuredosagenumb>
				<drugstructuredosageunit>3</drugstructuredosageunit>
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>600 mg, daily</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10054095</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct />
				<obtaindrugcountry />
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb>70</drugstructuredosagenumb>
				<drugstructuredosageunit>3</drugstructuredosageunit>
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>70 mg, daily</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10040617</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug />
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>FELBINAC</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a literature report from the Japanese Journal of Psychiatric Treatment 2015, 30 (3); p415-419 entitled "Two Cases of Chronic Somatic Pain Successfully Treated with Duloxetine".This is the Case No. 2. No adverse event due to Pfizer products occurred in the Case 1.An 80-year-old female patient started to receive pregabalin (product name unknown) oral from an unspecified date at 75 mg, daily for neuropathic pain. Co-suspect drugs included paroxetine hydrochloride (product name unknown) for depression, (LOXOPROFEN) at 180 mg/day for right shoulder pain, paracetamol (ACETAMINOPHEN) at 600 mg/day for neuropathic pain, duloxetine 20 mg/day. Medical history included depression. Concomitant medication included felbinac 70 mg/day for external use.The patient experienced drug-induced ileus on an unspecified date with outcome of recovered. The action taken in response to the event for pregabalin was permanently withdrawn.The patient was an 80-year-old woman.Chief complaint: Right shoulder painMedical history: DepressionHistory of present illness: Since around the spring of year X-2, the patient noticed such symptoms as fatigueability, mental concentration decreased and sleep loss without any particular inducing factors. On 26JulX-2, the patient visited the author's hospital as an outpatient basis. She was given a diagnosis of depression and prescribed sulpiride 50 mg/day, zolpidem 5 mg/day and ethyl loflazepate 1 mg/day, but the symptoms hardly improved. On 04AugX-2, the patient was admitted to the author's hospital. Treatment with paroxetine was started and after about a half year of treatment, depression remitted.Subsequent clinical course: In around SepX, pushing a walker for an aged person in the hospital triggered right shoulder pain that gradually worsened. Chest X-ray in the author's hospital showed no fracture. Treatment with topical felbinac 70 mg/day and oral loxoprofen 180 mg/day was started for pain, but no therapeutic effect was shown after all. Hematological/biochemical tests, thyroid function test, electrocardiography, chest X-ray, head CT scanning, and electroencephalography were performed just in case, but no abnormality was observed in each test. Therefore, the patient was referred to a pain clinic, where "a possibility of pain similar to complex regional pain syndrome" was diagnosed, thus stellate ganglion block was periodically started. In around FebX+1, the patient also began to complain of posterior cervical pain. In the pain clinic, she was told "the symptom might be associated with neuropathic pain due to spondylosis" and oral treatment with pregabalin 75 mg/day and acetaminophen 600 mg/day was started in addition to the star nerve block performed as before. However, the pain did not so much improve.In early JulX+1, duloxetine was added at 20 mg/day with the dose gradually increased every two weeks up to 60 mg/day. In the middle AugX+1, the patient reported that "pain had improved by 90%". While the scores of HAM-D (Hamilton Rating Scale for Depression) and MPQ (MacGill Pain Questionnaire) were 6 points and 32 points, respectively before introduction of duloxetine, HAM-D improved to 2 points and MPQ to 9 points. However, in OctX+1, ileus developed and in the end of OctX+1, the patient was transferred to hospital B. In the hospital, drug-induced ileus was pointed out; all the oral drugs were discontinued. In NovX+1, as ileus improved, the patient was transferred back to the author's hospital, but at that time, chronic pain as well as mood disorder was not observed. However, in early DecX+1, although mood disorder was not observed, the patient again began to complain of right upper arm pain. HAM-D was 3 points and MPQ was 21 points. The patient, who recognized the effects of duloxetine on pain during the previous treatment, gave consent to resuming the oral treatment. On the following day, treatment with duloxetine was started at 20 mg/day and two weeks later, the dose was gradually increased to 40 mg/day. Right upper arm pain subsequently significantly improved to the level before the patient was transferred. In FebX+2 (two months after the restart of treatment with duloxetine), HAM-D improved to 2 points and MPQ to 11 points.Pfizer is Marketing Authorization Holder of pregabalin, paroxetine hydrochloride in the reporter's country. This may be a duplicate report in situations where another Marketing Authorization Holder of pregabalin, paroxetine hydrochloride has submitted the same report to the regulatory authorities.No follow-up attempts needed. No further information expected.</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment>Causality cannot be excluded for the serious event drug-induced ileus and both Pfizer suspect drugs paroxetine and pregabalin, in this 80-year-old female patient. No detailed information on the event is available, at this time. Medical history only included depression. Pregabalin was prescribed for neuropathic pain due to spondylosis. Patient also received the non-Pfizer co-suspect products duloxetine, loxoprofen and paracetamol.The impact of this report on the benefit/risk profile of the Pfizer products is evaluated as part  of Pfizer procedures for safety evaluation, including  the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-36</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150408</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150330</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150330</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>30Mar2015 - Harimoto N et al. EJ license. 7107.</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-36</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle />
			<reportergivename />
			<reportermiddlename />
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reporterorganization />
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate />
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita Y-I et al. Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterology and Hepatology. 2015;30:656</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial />
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>40</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>2</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures>There was marked intrahepatic biliary dilatation, but normal common bile duct, on comupterized tomogram (CT) scan and MRCP. Her liver and biliary tract was normal on CT scan in the preceding 3 months. MELD score was 18 points and Child-Pugh score was 10. The histological examination of the explanted liver revealed vanishing bile duct syndrome (VBDS), with severe cholestasis and necrosis of hepatocyte. Cytokeratin 19 (the marker of bile duct) stains of resected liver were negative in the portal tract and small bile duct disappeared.</resultstestsprocedures>
			<reaction>
				<primarysourcereaction>Stevens-Johnson syndrome</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10042030</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>vanishing bile duct syndrome</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10054753</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>liver failure</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10024678</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>conjunctivitis</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10010741</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>maculopapular rash</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10025424</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>obstructive jaundice</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10029982</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>leucocytosis</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10024378</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>intrahepatic biliary dilatation</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10057202</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>cholestasis liver</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10024666</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>necrosis of hepatocyte</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10019692</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin conjugated</testname>
				<testresult>21</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood albumin</testname>
				<testresult>1.8</testresult>
				<testunit>g/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood alkaline phosphatase</testname>
				<testresult>895</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood bilirubin</testname>
				<testresult>27.9</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Gamma-glutamyltransferase</testname>
				<testresult>64</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>International normalized ratio</testname>
				<testresult>1.28</testresult>
				<testunit>unknown</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>White blood cell count</testname>
				<testresult>20580</testresult>
				<testunit>/mcL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Alanine aminotransferase</testname>
				<testresult>17</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>63</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Acetaminophen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10010741</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10010741</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10019692</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10019692</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10024378</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10024378</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10024666</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10024666</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10024678</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10024678</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025424</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025424</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029982</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029982</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10042030</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10042030</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10054753</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10054753</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10057202</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10057202</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was reported in a literature article and described the occurrence of stevens johnson syndrome in a 40-year-old female patient who received paracetamol (Acetaminophen) unknown for drug use for unknown indication. (Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita Y-I et al.,. Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. Journal of Gastroenterology and Hepatology 2015; 30: 656.)On an unknown date, the patient started Acetaminophen at an unknown dose and frequency. On an unknown date, an unknown time after starting Acetaminophen, the patient experienced stevens johnson syndrome (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required), vanishing bile duct syndrome (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required), liver failure (serious criteria GSK medically significant), conjunctivitis, maculopapular rash, obstructive jaundice (serious criteria GSK medically significant), leukocytosis, biliary dilatation (serious criteria GSK medically significant), liver cholestasis (serious criteria GSK medically significant) and hepatic necrosis (serious criteria GSK medically significant). The patient was treated with tacrolimus, mycophenolate mofetil, steroids nos (Steroids) and immunoglobulins nos (Immunoglobulin). The action taken with Acetaminophen was unknown. On an unknown date, the outcome of the stevens johnson syndrome, vanishing bile duct syndrome, liver failure, conjunctivitis, maculopapular rash and obstructive jaundice were recovered/resolved and the outcome of the leukocytosis, biliary dilatation, liver cholestasis and hepatic necrosis were unknown.The reporter considered the stevens johnson syndrome, vanishing bile duct syndrome and liver failure to be related to Acetaminophen. It was unknown if the reporter considered the conjunctivitis, maculopapular rash, obstructive jaundice, leukocytosis, biliary dilatation, liver cholestasis and hepatic necrosis to be related to Acetaminophen.Additional details,The patient with Steven Johnson syndrome (SJS) related to acetaminophen was admitted to a local hospital for steroid pulse and immunoglobulin therapy in November 2013. Although this led to resolution of her conjunctivitis and a maculopapular rash on her neck and arms, she developed progressive obstructive jaundice with signs of liver failure. Laboratory results revealed leucocytosis (WCC = 20,580/?L), alkaline phosphatase = 895 U/L, GGT = 64 U/L, AST = 63 U/L, ALT = 17 U/L, albumin = 1.8 g/dl, total serum bilirubin level = 27.9 mg/dl (direct bilirubin = 21.0 mg/dl), normal IgG4 and INR = 1.28. There was marked intrahepatic biliary dilatation, but normal common bile duct, on CT scan and MRCP. Her liver and biliary tract was normal on CT scan in the preceding 3 months. MELD score was 18 points and Child-Pugh score was 10.The patient was transferred to our university hospital for consideration of living-donor liver transplantation (LDLT), after the case was discussed with the Liver Transplantation Subcommittee. The left lobe was donated from her 53-year-old husband. Given blood type (AB+) of the donor was incompatible, the patient received rituximab treatment to decrease anti-blood-type antibodies. She underwent successful LDLT with duct to duct, left hepatico - common hepaticostomy. She received with tacrolimus with mycophenolate mofetil and steroids for postoperative immunosuppression. The histological examination of the explanted liver revealed vanishing bile duct syndrome (VBDS), with severe cholestasis and necrosis of hepatocyte. Cytokeratin 19 (the marker of bile duct) stains of resected liver were negative in the portal tract and small bile duct disappeared. She discharged home 68 days after LT with no evidence of recurrence of VBDS.The authors stated "Here, we report a rare case of acetaminophen induced SJS, VBDS and liver failure, requiring LDLT".</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment />
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-37</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150226</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150202</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150202</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>02Feb2015- Nanishi E et al. EJ License. 451.</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-37</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>E</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Nanishi</reporterfamilyname>
			<reporterorganization />
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate />
			<reporterpostcode>812-8582</reporterpostcode>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial />
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>4</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>1</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures>Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. Immunoglobulin levels and coagulation studies were unremarkable.</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10015108</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Drug reaction with eosinophilia and systemic symptoms</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10073508</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>jaundice</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10023126</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>5</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>abdominal pain</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10000081</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>5</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>generalized skin rash</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10049201</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>neutropenia</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10029354</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>thrombocytopenia</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10043554</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>interleukin-2 receptor increased</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10066315</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>ferritin increased</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10016459</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>hemophagocytic syndrome</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10058139</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Alanine aminotransferase</testname>
				<testresult>894</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>570</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin conjugated</testname>
				<testresult>5.6</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood bilirubin</testname>
				<testresult>7.8</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood immunoglobulin E</testname>
				<testresult>less than 10000</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood lactate dehydrogenase</testname>
				<testresult>637</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Body temperature</testname>
				<testresult>38</testresult>
				<testunit>degree C</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>CD8 lymphocytes</testname>
				<testresult>activated 72.2%</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>C-reactive protein</testname>
				<testresult>0.09</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Eosinophil count</testname>
				<testresult>4</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Gamma-glutamyltransferase</testname>
				<testresult>348</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Hemoglobin</testname>
				<testresult>11.7</testresult>
				<testunit>g/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Interleukin-2 receptor assay</testname>
				<testresult>6061000</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocyte count</testname>
				<testresult>55</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocyte morphology abnormal</testname>
				<testresult>5</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Monocyte count</testname>
				<testresult>10</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Neutrophil count</testname>
				<testresult>26</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Platelet count</testname>
				<testresult>143 X 10^9</testresult>
				<testunit>/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Serum ferritin</testname>
				<testresult>1492</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>White blood cell count</testname>
				<testresult>3.99 X 10^9</testresult>
				<testunit>/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Acetaminophen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod>7</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Cefditoren pivoxil</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod>7</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>CEFDITOREN PIVOXIL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was reported in a literature article and described the occurrence of drug reaction with eosinophilia and systemic symptoms in a 4-year-old male patient who received paracetamol (Acetaminophen) unknown for drug use for unknown indication. (Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection 2015; 48: 109-112.)Co-suspect products included cefditoren pivoxil unknown for drug use for unknown indication.On an unknown date, the patient started Acetaminophen at an unknown dose and frequency and cefditoren pivoxil at an unknown dose and frequency. On an unknown date, 7 days after starting Acetaminophen and cefditoren pivoxil, the patient experienced drug reaction with eosinophilia and systemic symptoms (serious criteria hospitalization and GSK medically significant), jaundice, abdominal pain, generalized rash, neutropenia (serious criteria GSK medically significant), thrombocytopenia, interleukin-2 receptor increased, ferritin increased and hemophagocytic syndrome (serious criteria GSK medically significant). The patient was treated with dexchlorpheniramine and glycyrrhizinate dipotassium. The action taken with Acetaminophen was unknown. The action taken with cefditoren pivoxil was unknown. On an unknown date, the outcome of the drug reaction with eosinophilia and systemic symptoms, generalized rash, neutropenia, thrombocytopenia, interleukin-2 receptor increased, ferritin increased and hemophagocytic syndrome were recovered/resolved and the outcome of the jaundice and abdominal pain were unknown.The reporter considered the drug reaction with eosinophilia and systemic symptoms, generalized rash, thrombocytopenia, interleukin-2 receptor increased, ferritin increased and hemophagocytic syndrome to be related to Acetaminophen and cefditoren pivoxil. It was unknown if the reporter considered the jaundice, abdominal pain and neutropenia to be related to Acetaminophen and cefditoren pivoxil.Additional details,A previously healthy 4-year-old boy was admitted to our hospital on the 14th day of illness because of prolonged fever, jaundice, and generalized skin eruption. The patient had received oral cefditorenepivoxil (CDTR-PI) and acetaminophen suppository from the 6th day to the 12th day of illness. Despite the defervescence on the 11th day of illness, jaundice and abdominal pain emerged. On the 13th day of illness, he presented to a practitioner again because of developing generalized skin rash. The laboratory findings showed increased levels of: aspartate aminotransferase, 1821 U/L; alanine aminotransferase, 1777 U/L; total bilirubin, 6.8 mg/dL; and direct bilirubin, 5.1 mg/dL. He was then referred to us for further management.On admission, his body temperature was 38.0_C. Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Mucous membranes and conjunctivas were spared. There was cervical lymphadenopathy, hepatomegaly, but no splenomegaly. Complete blood counts showed a leukocyte count of 3.99 X 10^9/L with 26% segmented neutrophils, 55% lymphocytes, 10% monocytes, 4% eosinophils, and 5% atypical lymphocytes, a hemoglobin concentration of 11.7 g/dL and a platelet count of 143 X 10^9/L. Blood chemistry showed: total bilirubin, 7.8 mg/dL; direct bilirubin, 5.6 mg/dL; aspartate aminotransferase, 570 U/L; alanine aminotransferase, 894 U/L; lactate dehydrogenase, 637 U/L; and gamma-glutamyl transpeptidase, 348 U/L. C-reactive protein concentration was 0.09 mg/dL. Serum levels of ferritin (1492 mg/dL) and soluble interleukin-2 receptor (6061 U/mL) were both high. Immunoglobulin levels and coagulation studies were unremarkable (immunoglobulin E &lt; 10 U/mL). Surface maker analysis of the peripheral blood lymphocytes showed a reversed CD4/CD8 ratio (0.45) and a prominently increased proportion of activated CD8?T cells (72.2%). There were past inactive infections, but no reactivations of cytomegalovirus or HHV-6. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. A high copy number of EBV-DNA (3 X 10^6 copies/L of peripheral blood) was detected by real-time polymerase chain reaction. LTT for acetaminophen [stimulation index (SI) 555%] or CDTR-PI (SI 314%) was highly positive. The diagnosis of DRESS was made because the patient fulfilled all but one criteria of eosinophilia. Dexchlorpheniramine and glycyrrhizinate were started with no use of the other drugs including antipyretics. All symptoms resolved until the cessation of therapy on the 19th day of illness. Negative LTT for acetaminophen (SI 81%) or CDTR-PI (SI 71%) was confirmed 2 months later. Thereafter, skin eruption did not appear when acetaminophen was administered at the chance of fever.</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment />
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-38</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry />
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150222</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150206</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>Literature</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-38</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm />
		<primarysource>
			<reportertitle />
			<reportergivename>E</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Nanishi</reporterfamilyname>
			<reporterorganization />
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate />
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage />
			<patientonsetageunit />
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex />
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures>soluble interleukin-2 receptor was 6061 U/mL</resultstestsprocedures>
			<reaction>
				<primarysourcereaction>DRESS syndrome</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10058899</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Alanine aminotransferase</testname>
				<testresult>1777</testresult>
				<testunit>U/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>1821</testresult>
				<testunit>U/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>894</testresult>
				<testunit>U/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin direct</testname>
				<testresult>5.1</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin direct</testname>
				<testresult>5.6</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin total</testname>
				<testresult>6.8</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin total</testname>
				<testresult>7.8</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Immunoglobulin E</testname>
				<testresult />
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lactate dehydrogenase</testname>
				<testresult>637</testresult>
				<testunit>U/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Body temperature</testname>
				<testresult />
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>C-reactive protein</testname>
				<testresult>0.09</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Eosinophils</testname>
				<testresult>4</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>GGTP</testname>
				<testresult>348</testresult>
				<testunit>U/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Hemoglobin</testname>
				<testresult>11.7</testresult>
				<testunit>g/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocytes</testname>
				<testresult>55</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Atypical lymphocytes</testname>
				<testresult>5</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Monocytes</testname>
				<testresult>10</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Segmented neutrophil count</testname>
				<testresult>26</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Platelet count</testname>
				<testresult>143</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Ferritin</testname>
				<testresult>1492</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Leucocyte count</testname>
				<testresult>3.99</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct />
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform>Suppository</drugdosageform>
				<drugadministrationroute>54</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10016558</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct />
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10016558</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>CEFDITOREN PIVOXIL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was derived from a scientific literature which describes drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection.The article describes a 4-year-old male child who was hospitalized for drug reaction with eosinophilia and systemic symptoms (DRESS) while on therapy with acetaminophen suppository and cefditoren pivoxil for fever.The child was admitted to the hospital on the fourteenth day of illness because of prolonged fever, jaundice, and generalized skin eruption. The patient had received oral cefditoren pivoxil and acetaminophen suppository from the 6th day to the 12th day of illness. Despite the defervescence on the 11th day of illness, jaundice and abdominal pain emerged. On the 13th day of illness, he presented to a practitioner again because of developing generalized skin rash. The laboratory findings showed increased levels of aspartate aminotransferase at 1821 U/L, alanine aminotransferase at 1777 U/L, total bilirubin at 6.8 mg/dL and direct bilirubin at 5.1 mg/dL. He was then referred to the reporter for further management. On admission, his body temperature was 38.0 Dec C. Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Mucous membranes and conjunctivas were spared. There was cervical lymphadenopathy, hepatomegaly, but no splenomegaly.Complete blood counts showed a leukocyte count of 3.99 X 109/L with 26% segmented neutrophils, 55% lymphocytes, 10% monocytes, 4% eosinophils, and 5% atypical lymphocytes, a hemoglobin concentration of 11.7 g/dL and a platelet count of 143 X 109/L. Blood chemistry showed total bilirubin at 7.8 mg/dL, direct bilirubin at 5.6 mg/dL, aspartate aminotransferase at 570 U/L, alanine aminotransferase at 894 U/L, lactate dehydrogenase at 637 U/L and g-glutamyl transpeptidase at 348 U/L. C-reactive protein concentration was 0.09 mg/dL. Serum levels of ferritin (1492 mg/dL) and soluble interleukin-2 receptor (6061 U/mL) were both high. Immunoglobulin levels and coagulation studies were unremarkable (immunoglobulin E was less than 10 U/mL). Surface maker analysis of the peripheral blood lymphocytes showed a reversed CD4/CD8 ratio (0.45) and a prominently increased proportion of activated CD8T cells (72.2%). There were past inactive infections, but no reactivation of Cytomegalovirus or HHV-6. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. A high copy number of EBV-DNA (3X106 copies/L of peripheral blood) was detected by real-time polymerase chain reaction. Lymphocyte transformation test (LTT) for acetaminophen [stimulation index (SI) 555%] or cefditoren pivoxil (SI 314%) was highly positive. The diagnosis of DRESS was made because the patient fulfilled all but one criteria of eosinophilia. Dexchlorpheniramine and glycyrrhizinate were started with no use of the other drugs including antipyretics. All symptoms resolved until the cessation of therapy on the 19th day of illness. Negative LTT for acetaminophen (SI 81%) or cefditoren pivoxil (SI 71%) was confirmed 2 months later. Thereafter, skin eruption did not appear when acetaminophen was administered at the chance of fever.Authors comment:Drug reactions in childhood are often challenging to diagnose because of accompanying viral diseases presenting cutaneous manifestation. The diagnostic criteria of DRESS/DIHS overlap the representative manifestations of infectious mononucleosis (IM). DRESS was first confirmed by the positive LTT in this pediatric patient with primary EBV infection. This observation suggests an unexpected utility of LTT for the correct diagnosis of DRESS associated with primary EBV infection. Reactivation of herpes virus infection concurrent with drug hypersensitivity is considered specific to DRESS. The patient showed slight neutropenia and thrombocytopenia, but no eosinophilia. High serum levels of soluble interleukin-2 receptor and ferritin during the acute phase indicated the excessive immune activation leading to hemophagocytic syndrome, when eosinophilia is unusual. Pituitary adrenal axis might result in the modest increase of eosinophil counts during the convalescent phase (18th day of illness: 0.29 X 109/L). Severe immune responses to the virus reactivation may explain the clinical manifestations of DRESS. The culprit drugs triggered the virus replication in EBV transformed B cells from the patient. Both LTT for acetaminophen and cefditoren pivoxil were definitely positive in the patient. These drugs are chemically different and are metabolized through different pathways. Multidrug hypersensitivity rather than the cross reaction may explain the distinct manifestation although no skin patch test was performed. In the patient, the positive result of LTT came to be negative with the favorable clinical course. The proportion of circulating T cell subsets from patients affects the in vitro result of LTT. Functional regulatory T cells at the acute stage of DRESS may serve to prevent the activation and expansion of drug-specific T cells. However, the proportion of regulatory T cells was reported to decrease in patients with primary infection, but not with reactivation of EBV. Further study is needed to determine the sensitivity of LLT during the acute and convalescent phase of primary EBV infection assessed by the analysis of functional T cell subpopulation. Sequential LLT may be useful to determine the ominous hypersensitivity to drugs in patients with the primary infection of EBV.Literary Citation:  Nanishi E, Hoshina T, Ohga S,  Nishio H,  Hara T. Drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection. Journal of Microbiology, Immunology and Infection 48; 2015: 109-112.BMS Medical Evaluation Comment :This patient was diagnosed with drug rash with eosinophilia and systemic symptoms (DRESS) while on acetaminophen and cefditoren therapy. Based on the nature of the event and considering the positive lymphocyte transformation test for acetaminophen and cefditoren, the event was considered a drug reaction to both the suspect medications.</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment>This patient was diagnosed with drug rash with eosinophilia and systemic symptoms (DRESS) while on acetaminophen and cefditoren therapy. Based on the nature of the event and considering the positive lymphocyte transformation test for acetaminophen and cefditoren, the event was considered a drug reaction to both the suspect medications.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-39</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150220</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150206</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>Literature</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-39</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle />
			<reportergivename>E</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Nanishi</reporterfamilyname>
			<reporterorganization />
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate />
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>UNK</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage />
			<patientonsetageunit />
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex />
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures />
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10015108</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Drug reaction with eosinophilia and systemic symptoms</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10073508</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocyte transformation test</testname>
				<testresult>positive for cefditoren-pivoxil and acetaminophen</testresult>
				<testunit>Report</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PARACETAMOL</medicinalproduct>
				<obtaindrugcountry>RO</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute>65</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessed</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Cefditoren</medicinalproduct>
				<obtaindrugcountry>IN</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute>65</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>CEFDITOREN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessed</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This case, manufacturer control number 2015RR-93179, from JAPAN, refers to a patient of unspecified age or gender who developed drug reaction with eosinophilia and systemic symptoms following treatment with cefditoren pivoxil and acetaminophen.The case was reported in literature.The case was considered serious because the ADR was medically significant.Patient current condition:Epstein-Barr virus infection.The patient received the following suspect products:Cefditoren pivoxil: for unknown indication.Acetaminophen: for unknown indication.On an unspecified date, the patient developed drug reaction with eosinophilia and systemic symptoms following treatment with cefditoren pivoxil and acetaminophen.Reaction text: "We report a drug reaction with eosinophilia and systemic symptoms case of primary Epstein-Barr virus (EBV) infection, in which the diagnosis was first confirmed by lymphocyte transformation tests (LTT). LTTs were positive for cefditoren-pivoxil and acetaminophen. LTT, EBV load, and anti-EBV antibodies could allow early diagnosis of drug reaction with eosinophilia and systemic symptoms, which masquerades with the clinical features of infectious mononucleosis."The outcome of the ADR was not reported at the time of this report.Ranbaxy medical reviewer's assessment:The case is rated as serious and unexpected with Acetaminophen use in EU.The causal role of Acetaminophen and Cefditoren pivoxil cannot be properly assessed as insufficient data is provided regarding  dose, route of administration, frequency and indication of suspected drugs, time onset of ADR, patient's medical history and concomitant medication. Further details are required in order to proper evaluate the report.The SPC of Acetaminophen lists cutaneous hypersensitivity reactions but does not list drug reaction with eosinophilia and systemic symptoms (which is a more specific form of hypersensitivity).</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion>17.1</senderdiagnosismeddraversion>
				<senderdiagnosis>10073508</senderdiagnosis>
				<sendercomment>The case is rated as serious and unexpected with Acetaminophen use in EU.The causal role of Acetaminophen and Cefditoren pivoxil cannot be properly assessed as insufficient data is provided regarding  dose, route of administration, frequency and indication of suspected drugs, time onset of ADR, patient's medical history and concomitant medication. Further details are required in order to proper evaluate the report.The SPC of Acetaminophen lists cutaneous hypersensitivity reactions but does not list drug reaction with eosinophilia and systemic symptoms (which is a more specific form of hypersensitivity).</sendercomment>
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-40</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150215</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150206</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist />
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-40</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm />
		<primarysource>
			<reportertitle />
			<reportergivename>Takayuki</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Hoshina</reporterfamilyname>
			<reporterorganization>Graduate School of Medical Sciences</reporterorganization>
			<reporterdepartment>Department of Pediatrics</reporterdepartment>
			<reporterstreet>Kyushu University3-1-1 Maidashi</reporterstreet>
			<reportercity>Higashi-ku</reportercity>
			<reporterstate>Fukuoka</reporterstate>
			<reporterpostcode>812-8582</reporterpostcode>
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>4</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>1</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures />
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10015108</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Abdominal pain emerged</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10000081</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Body temperature was 38.0 degree centigrade/prolonged fever</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10073718</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Cervical lymphadenopathy</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10025200</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Drug reaction with eosinophilia and systemic symptoms</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10058899</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Generalized skin rash/Generalized skin eruption</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10037858</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hepatomegaly</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10019842</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Jaundice</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10023126</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pruritic maculopapular eruption and generalized skin rash</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10025422</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pruritic maculopapular eruption/generalized skin rash</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10037884</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Skin and bulbar conjunctiva were icteric</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10021206</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Skin and bulbar conjunctiva were icteric</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10048245</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Slight neutropenia</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10029354</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Thrombocytopenia</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10043554</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Alanine aminotransferase</testname>
				<testresult>1777</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Alanine aminotransferase</testname>
				<testresult>894</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>1821</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>570</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin conjugated</testname>
				<testresult>5.1</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin conjugated</testname>
				<testresult>5.6</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin total</testname>
				<testresult>6.8</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin total</testname>
				<testresult>7.8</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Immunoglobulin E</testname>
				<testresult>Less than 10 U/mL</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lactate dehydrogenase</testname>
				<testresult>637</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Body temperature</testname>
				<testresult>38.0</testresult>
				<testunit>C</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>CD4/CD8 ratio</testname>
				<testresult>0.45</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>C-reactive protein</testname>
				<testresult>0.09</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Gamma glutamyl transpeptidase</testname>
				<testresult>348</testresult>
				<testunit>U/l</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Haemoglobin</testname>
				<testresult>11.7</testresult>
				<testunit>g/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Interleukin-2 receptor assay</testname>
				<testresult>6061</testresult>
				<testunit>U/ml</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocyte transformation test</testname>
				<testresult>Positive</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Platelet count</testname>
				<testresult>143</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>PCR</testname>
				<testresult>Abnormal</testresult>
				<testunit />
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Ferritin</testname>
				<testresult>1492</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>White blood cell count</testname>
				<testresult>3.99</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct />
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute>54</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10070592</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10019842</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10019842</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021206</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021206</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025200</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025200</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025422</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025422</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10037858</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10037858</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10037884</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10037884</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048245</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048245</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073718</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073718</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct />
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10070592</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>CEFDITOREN PIVOXIL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10019842</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021206</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025200</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10025422</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10037858</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10037884</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048245</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073718</drugreactionasses>
					<drugassessmentsource>2</drugassessmentsource>
					<drugassessmentmethod>EVCTM</drugassessmentmethod>
					<drugresult>1</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2015JP015840 is an initial literature report received on 06 Feb 2015. The author discussed about drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection. This report refers to a 04 year old male patient. The patient had received oral cefditoren-pivoxil (CDTR-PI) and acetaminophen (manufacturer unknown) suppository from the 6th day to the 12th day of illness. Despite the defervescence on the 11th day of illness, jaundice and abdominal pain emerged. On the 13th day of illness, he presented to a practitioner again because of developing generalized skin rash. The patient was admitted to our hospital on the 14th day of illness because of prolonged fever, jaundice, and generalized skin eruption. The laboratory findings showed increased levels of aspartate aminotransferase (AST) at 1821 U/L; alanine aminotransferase (ALT) at 1777 U/L, total bilirubin, 6.8 mg/dL and direct bilirubin at 5.1 mg/dL. He was then referred for further management. On admission, his body temperature was 38.0 degree centigrade. Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Mucous membranes and conjunctivas were spared. There was cervical lymphadenopathy and hepatomegaly, but no splenomegaly. Complete blood counts showed a leukocyte count of 3.99 X 109/L with 26% segmented neutrophils, 55% lymphocytes, 10% monocytes, 4% eosinophils and 5% atypical lymphocytes, a hemoglobin concentration of 11.7 g/dL and a platelet count of 143 X 109/L. Blood chemistry showed a total bilirubin of 7.8 mg/dL, direct bilirubin of 5.6 mg/dL, AST of 570 U/L, ALT of 894 U/L; lactate dehydrogenase of 637 U/L and g-glutamyl transpeptidase of 348 U/L. C-reactive protein concentration was 0.09 mg/dL. Serum levels of ferritin (1492 mg/dL) and soluble interleukin-2 receptor (6061 U/mL) were both high. Immunoglobulin levels and coagulation studies were unremarkable (immunoglobulin E &lt; 10 U/mL). Surface maker analysis of the peripheral blood lymphocytes showed a reversed CD4/CD8 ratio (0.45) and a prominently increased proportion of activated CD8T cells (72.2%). There were past inactive infections, but no reactivations of cytomegalovirus or HHV-6. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. A high copy number of EBV-DNA (3 X 106 copies/L of peripheral blood) was detected by real-time polymerase chain reaction. Lymphocyte transformation tests (LTT) for acetaminophen [stimulation index (SI) 555%] or CDTR-PI (SI 314%) was highly positive. The diagnosis of drug reaction with eosinophilia and systemic symptoms (DRESS) was made because the patient fulfilled all but one criteria of eosinophilia. Dexchlorpheniramine and glycyrrhizinate were started with no use of the other drugs including antipyretics. The present patient showed slight neutropenia and thrombocytopenia, but no eosinophilia. In the present patient, the positive result of LTT came to be negative with the favorable clinical course. All symptoms resolved until the cessation of therapy on the 19th day of illness. Negative LTT for acetaminophen (SI 81%) or CDTR-PI (SI 71%) was confirmed two months later. Thereafter, skin eruption did not appear when acetaminophen was administered at the chance of fever. The author commented that LTTs were positive for cefditoren-pivoxil and acetaminophen.</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment />
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-41</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150211</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150202</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150202</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>02Feb2015- Nanishi E et al. EJ License. 451.</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-41</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle />
			<reportergivename />
			<reportermiddlename />
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reporterorganization />
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate />
			<reporterpostcode>812-8582</reporterpostcode>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial />
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>4</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>1</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures>Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. Immunoglobulin levels and coagulation studies were unremarkable.</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10015108</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Drug reaction with eosinophilia and systemic symptoms</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10073508</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>jaundice</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10023126</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>5</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>abdominal pain</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10000081</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>5</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>generalized skin rash</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10049201</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>neutropenia</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10029354</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>thrombocytopenia</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10043554</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>interleukin-2 receptor increased</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10066315</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>ferritin increased</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10016459</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>hemophagocytic syndrome</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10058139</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted />
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat />
				<testdate />
				<testname>Alanine aminotransferase</testname>
				<testresult>894</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Aspartate aminotransferase</testname>
				<testresult>570</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Bilirubin conjugated</testname>
				<testresult>5.6</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood bilirubin</testname>
				<testresult>7.8</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood immunoglobulin E</testname>
				<testresult>less than 10000</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Blood lactate dehydrogenase</testname>
				<testresult>637</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Body temperature</testname>
				<testresult>38</testresult>
				<testunit>degree C</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>CD8 lymphocytes</testname>
				<testresult>activated 72.2%</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>C-reactive protein</testname>
				<testresult>0.09</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Eosinophil count</testname>
				<testresult>4</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Gamma-glutamyltransferase</testname>
				<testresult>348</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Hemoglobin</testname>
				<testresult>11.7</testresult>
				<testunit>g/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Interleukin-2 receptor assay</testname>
				<testresult>6061000</testresult>
				<testunit>u/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocyte count</testname>
				<testresult>55</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Lymphocyte morphology abnormal</testname>
				<testresult>5</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Monocyte count</testname>
				<testresult>10</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Neutrophil count</testname>
				<testresult>26</testresult>
				<testunit>%</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Platelet count</testname>
				<testresult>143 X 10^9</testresult>
				<testunit>/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>Serum ferritin</testname>
				<testresult>1492</testresult>
				<testunit>mg/dL</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat />
				<testdate />
				<testname>White blood cell count</testname>
				<testresult>3.99 X 10^9</testresult>
				<testunit>/L</testunit>
				<lowtestrange />
				<hightestrange />
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Acetaminophen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod>7</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Cefditoren pivoxil</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod>7</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration />
				<drugadditional />
				<activesubstance>
					<activesubstancename>CEFDITOREN PIVOXIL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10000081</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10016459</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10023126</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10029354</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Unknown</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10043554</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10049201</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058139</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10066315</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was reported in a literature article and described the occurrence of drug reaction with eosinophilia and systemic symptoms in a 4-year-old male patient who received paracetamol (Acetaminophen) unknown for drug use for unknown indication. (Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection 2015; 48: 109-112.)Co-suspect products included cefditoren pivoxil unknown for drug use for unknown indication.On an unknown date, the patient started Acetaminophen at an unknown dose and frequency and cefditoren pivoxil at an unknown dose and frequency. On an unknown date, 7 days after starting Acetaminophen and cefditoren pivoxil, the patient experienced drug reaction with eosinophilia and systemic symptoms (serious criteria hospitalization and GSK medically significant), jaundice, abdominal pain, generalized rash, neutropenia (serious criteria GSK medically significant), thrombocytopenia, interleukin-2 receptor increased, ferritin increased and hemophagocytic syndrome (serious criteria GSK medically significant). The patient was treated with dexchlorpheniramine and glycyrrhizinate dipotassium. The action taken with Acetaminophen was unknown. The action taken with cefditoren pivoxil was unknown. On an unknown date, the outcome of the drug reaction with eosinophilia and systemic symptoms, generalized rash, neutropenia, thrombocytopenia, interleukin-2 receptor increased, ferritin increased and hemophagocytic syndrome were recovered/resolved and the outcome of the jaundice and abdominal pain were unknown.The reporter considered the drug reaction with eosinophilia and systemic symptoms, generalized rash, thrombocytopenia, interleukin-2 receptor increased, ferritin increased and hemophagocytic syndrome to be related to Acetaminophen and cefditoren pivoxil. It was unknown if the reporter considered the jaundice, abdominal pain and neutropenia to be related to Acetaminophen and cefditoren pivoxil.Additional details,A previously healthy 4-year-old boy was admitted to our hospital on the 14th day of illness because of prolonged fever, jaundice, and generalized skin eruption. The patient had received oral cefditorenepivoxil (CDTR-PI) and acetaminophen suppository from the 6th day to the 12th day of illness. Despite the defervescence on the 11th day of illness, jaundice and abdominal pain emerged. On the 13th day of illness, he presented to a practitioner again because of developing generalized skin rash. The laboratory findings showed increased levels of: aspartate aminotransferase, 1821 U/L; alanine aminotransferase, 1777 U/L; total bilirubin, 6.8 mg/dL; and direct bilirubin, 5.1 mg/dL. He was then referred to us for further management.On admission, his body temperature was 38.0_C. Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Mucous membranes and conjunctivas were spared. There was cervical lymphadenopathy, hepatomegaly, but no splenomegaly. Complete blood counts showed a leukocyte count of 3.99 X 10^9/L with 26% segmented neutrophils, 55% lymphocytes, 10% monocytes, 4% eosinophils, and 5% atypical lymphocytes, a hemoglobin concentration of 11.7 g/dL and a platelet count of 143 X 10^9/L. Blood chemistry showed: total bilirubin, 7.8 mg/dL; direct bilirubin, 5.6 mg/dL; aspartate aminotransferase, 570 U/L; alanine aminotransferase, 894 U/L; lactate dehydrogenase, 637 U/L; and gamma-glutamyl transpeptidase, 348 U/L. C-reactive protein concentration was 0.09 mg/dL. Serum levels of ferritin (1492 mg/dL) and soluble interleukin-2 receptor (6061 U/mL) were both high. Immunoglobulin levels and coagulation studies were unremarkable (immunoglobulin E &lt; 10 U/mL). Surface maker analysis of the peripheral blood lymphocytes showed a reversed CD4/CD8 ratio (0.45) and a prominently increased proportion of activated CD8?T cells (72.2%). There were past inactive infections, but no reactivations of cytomegalovirus or HHV-6. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. A high copy number of EBV-DNA (3 X 10^6 copies/L of peripheral blood) was detected by real-time polymerase chain reaction. LTT for acetaminophen [stimulation index (SI) 555%] or CDTR-PI (SI 314%) was highly positive. The diagnosis of DRESS was made because the patient fulfilled all but one criteria of eosinophilia. Dexchlorpheniramine and glycyrrhizinate were started with no use of the other drugs including antipyretics. All symptoms resolved until the cessation of therapy on the 19th day of illness. Negative LTT for acetaminophen (SI 81%) or CDTR-PI (SI 71%) was confirmed 2 months later. Thereafter, skin eruption did not appear when acetaminophen was administered at the chance of fever.</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment />
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-42</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150213</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150204</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150204</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist />
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-42</companynumb>
		<duplicate>1</duplicate>
		<casenullification />
		<nullificationreason />
		<medicallyconfirm />
		<reportduplicate>
			<duplicatesource />
			<duplicatenumb>201502658</duplicatenumb>
		</reportduplicate>
		<primarysource>
			<reportertitle />
			<reportergivename>Sayaka</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Takahashi</reporterfamilyname>
			<reporterorganization>Yamanashi Prefectural Central Hospital</reporterorganization>
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate>Yamanashi</reporterstate>
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>2</qualification>
			<literaturereference>Takahashi S. An Effort for Proposal of Prescription and Efforts to Solve Problems by a Pharmacist in a Nutrition Support Team (NST). J Jpn Soc Parenter Enteral Nutr. 2015;30(1):510</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>73</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>1</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext>The patient's other history of illicit drug use/drug abuse, alcohol use and smoking was not reported.</patientmedicalhistorytext>
			<resultstestsprocedures />
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10038444</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>for 30 years</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10017758</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10061965</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10061105</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>INAPPETENCE</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10054792</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRAMCET</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb>GB Mkt</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>Non-Gruenenthal</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10070592</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10054792</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10054792</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NAUZELIN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10070592</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional>Reported drug name: Nauzelin OD</drugadditional>
				<activesubstance>
					<activesubstancename>DOMPERIDONE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Manufacturer Control Number: 2015-11000This spontaneous literature case from Japan was reported by a pharmacist via license partner and was initially received on 04-Feb-2015. It concerns a 73-year-old male patient (height and weight unknown).The patient's medical history and concurrent conditions included renal failure chronic, gastric cancer, gastrectomy and dialysis. The patient's other history of illicit drug use/drug abuse, alcohol use and smoking was not reported.The patient was treated with tramadol hydrochloride, paracetamol (Tramcet, film-coated tablet, oral) initiated on an unspecified date (posology unknown) for unknown indication.Other suspected medication included domperidone (Nauzelin, tablet, oral)  initiated on an unspecified date (posology unknown) for unknown indication.No relevant concomitant medication was reported.On an unspecified date, the patient experienced decreased appetite.It was reported that the patient had been undergoing dialysis for chronic renal failure for 30 years, until the time of this report.On an unspecified date, the patient was hospitalized for pleural effusion retention, dyspnoea and inappetence. The reporter thought that the continuous administration of an analgesic drug such as tramadol/apap tablet and an adverse drug reaction to an antiemetic drug, domperidone orodispersible tablet, were the causes of the event inappetence. The reporter stated that a proposal was made to reduce the doses of tramadol/apap and domperidone. Action taken with tramadol/apap and domperidone was not reported.The patient's outcome was not reported for the event inappetence.The reporter stated that the event of inappetence was related to the suspect drug tramadol/apap and domperidone.No relevant laboratory data were reported.No treatment of the AE was reported.No further information was available.Literature citation:takahashi s. an effort for proposal of prescription and efforts to solve problems by a pharmacist in a nutrition support team (nst). j jpn soc parenter enteral nutr. 2015; 30(1): 510***Third party case numbers:e2b company number: jp-jnjfoc-20150206714e2b report duplicate: 201502658</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment>Decreased appetite is assessed as serious.Decreased appetite is listed in the Company Core Datasheet of tramadol hydrochloride, paracetamol (oral).Decreased appetite is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol.The information in this single case does not appear to alter the favorable benefit to risk ratio of tramadol hydrochloride, paracetamol.Time to onset was not provided, but the sequence of events suggests a plausible temporal relationship. Appetite disorders belong to the known reactions for tramadol hydrochloride, paracetamol and are thus assessed to be possibly related to its administration, in the absence of alternative explanations.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-43</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150313</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150304</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150304</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist />
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-43</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm />
		<primarysource>
			<reportertitle>DR</reportertitle>
			<reportergivename>Masaru</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Takemura</reporterfamilyname>
			<reporterorganization>Dokkyo Medical University</reporterorganization>
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate>Tochigi</reporterstate>
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Takemura M. Experience of Two Cases Presenting with Withdrawal Signs Due to Interruption of Oral Treatment with Weak Opioid. 44th Annual Meeting of the Japanese Society for the Study of Chronic Pain - Abstract of Congress. 2015;101:3</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>72</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>1</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext>The patient's history of drug abuse/illicit drug use, alcohol and smoking was not reported.</patientmedicalhistorytext>
			<resultstestsprocedures />
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10033371</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>(underlying disease)</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10041591</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>(underlying disease)</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10017577</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>(underlying disease)</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>WITHDRAWAL REACTION</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10048008</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRAMCET</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb>GB Mkt</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>Non-Gruenenthal</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>32</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>1 DF, 2/day</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration>183</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>6</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct />
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry />
				<drugauthorizationholder>Unknown Manufacturer</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>BUPRENORPHINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Unlikely</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Manufacturer Control Number: 2015-11646This spontaneous literature case from Japan was reported by a physician via license partner and was initially received on 04-Mar-2015. It concerns a 72-year-old male patient (height and weight unknown).The patient's medical history and concurrent conditions included pain, spinal osteoarthritis and gait disturbance. The patient's history of drug abuse/illicit drug use, alcohol and smoking was not reported.The patient was treated with tramadol hydrochloride, paracetamol (Tramcet, film-coated tablet, oral) 1 df 2/day initiated on an unspecified date for pain.No other suspected medication was reported.No relevant concomitant medication was reported.On an unspecified date, the patient experienced withdrawal syndrome.It was reported that on an unspecified date, the patient was diagnosed with difficulty in walking due to osteoarthritis of lumbar spine and was prescribed tramadol/apap, for approximately 6 months at the previous hospital. However, the symptoms did not improve, for which he was referred to the author's hospital.On an unspecified date, he complained of severe clinical symptoms compared with imaging findings, based on which a high risk for abuse of/dependence on the opioid analgesic was considered. Accordingly, switching to buprenorphine patch was suggested. At the same time that application of buprenorphine patch was started, tramadol/apap was discontinued because the dose of oral tramadol/apap was low.However, the patient experienced irritated feeling, epigastric discomfort and yawning and became sweaty approximately 8 hours after the application of buprenorphine, base on which withdrawal signs were considered, and tramadol/apap was resumed immediately. As a result, the symptoms disappeared. The patient had recovered from withdrawal reaction on an unspecified date.No relevant laboratory data were reported.No treatment of the AE was reported.The outcome of withdrawal syndrome was reported as recovered/resolved.No further information was available.Literature citation:takemura m. experience of two cases presenting with withdrawal signs due to interruption of oral treatment with weak opioid. abstract of congress. 2015; 28:101:***Third party case numbers:e2b company number: jp-jnjfoc-20150306429</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment>Withdrawal syndrome is assessed as serious.Withdrawal syndrome is listed in the Company Core Data Sheet of tramadol hydrochloride, paracetamol (oral) and unlisted in the Company Core Data Sheet of buprenorphine (transdermal).Withdrawal syndrome is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol and unlikely related to buprenorphine.The information in this single case does not appear to alter the favorable benefit to risk ratio of tramadol hydrochloride, paracetamol nor buprenorphine transdermal.The additionally reported events of irritated feeling, epigastric discomfort, yawning and sweaty were deleted as they are considered to be symptoms of the diagnosed withdrawal.Based on the available information, time to onset is plausible, and withdrawal syndrome belongs to the known reaction pattern of tramadol hydrochloride, paracetamol. According to the reporter, the withdrawal symptoms occurred after discontinuation of tramadol hydrochloride, paracetamol, and the event resolved after reintroducing tramadol hydrochloride, paracetamol. Hence, withdrawal syndrome is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol.Buprenorphine, which was started on the day of the withdrawal reaction as replacement therapy for tramadol hydrochloride, paracetamol, was also captured as a suspect drug. As tramadol hydrochloride, paracetamol is known to possibly induce withdrawal symptoms after discontinuation, the company considered withdrawal syndrome to be unlikely related to the administration of buprenorphine.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-44</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150313</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150304</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150304</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist />
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-44</companynumb>
		<duplicate>1</duplicate>
		<casenullification />
		<nullificationreason />
		<medicallyconfirm />
		<reportduplicate>
			<duplicatesource />
			<duplicatenumb>201504950</duplicatenumb>
		</reportduplicate>
		<primarysource>
			<reportertitle>DR</reportertitle>
			<reportergivename>Masaru</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Takemura</reporterfamilyname>
			<reporterorganization>Dokkyo Medical University</reporterorganization>
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate>Tochigi</reporterstate>
			<reporterpostcode />
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Takemura M. Experience of Two Cases Presenting with Withdrawal Signs Due to Interruption of Oral Treatment with Weak Opioid. 44th Annual Meeting of the Japanese Society for the Study of Chronic Pain - Abstract of Congress. 2015;101:3</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>44</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>2</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext>The patient's history of drug abuse/illicit drug use, alcohol use and smoking was not reported</patientmedicalhistorytext>
			<resultstestsprocedures />
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10033371</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10029173</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>stellate ganglion block</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10041554</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>cervical cord injury</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10039203</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment>approximately 10 years before</patientmedicalcomment>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>BUPRENORPHINE HYDROCHLORIDE</patientdrugname>
				<patientdrugstartdateformat />
				<patientdrugstartdate />
				<patientdrugenddateformat />
				<patientdrugenddate />
				<patientindicationmeddraversion />
				<patientdrugindication />
				<patientdrgreactionmeddraversion>17.1</patientdrgreactionmeddraversion>
				<patientdrugreaction>10048768</patientdrugreaction>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>WITHDRAWAL REACTION</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10048008</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>THERAPY INTERRUPTED</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10064294</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>1</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRAMCET</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb>GB Mkt</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>Non-Gruenenthal</drugauthorizationholder>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>32</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>2 DF, 3/day</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>6</actiondrug>
				<drugrecurreadministration>2</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Not applicable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRAMCET</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb>GB Mkt</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>Non-Gruenenthal</drugauthorizationholder>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>32</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>2 DF, 3/day</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion />
				<drugindication />
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>6</actiondrug>
				<drugrecurreadministration>2</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Not applicable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Manufacturer Control Number: 2015-11648This spontaneous literature case from Japan was reported by a physician via license partner and was initially received on 04-Mar-2015. It concerns a 44-year-old female patient (height and weight unknown).The patient's medical history and concurrent conditions included pain, nerve block, spinal cord injury cervical, road traffic accident and dermatosis under previous buprenorphine hydrochloride treatment.The patient was treated with tramadol hydrochloride, paracetamol (Tramcet, film-coated tablet, oral) 2 df 3/day initiated on an unspecified date for pain.No other suspected medication was reported.No relevant concomitant medication was reported.On an unspecified date, the patient experienced withdrawal syndrome.Although the patient had been receiving treatment with stellate ganglion block for cervical cord injury after traffic injury experienced approximately 10 years before, no effective alleviation of pain had been achieved, for which prescription of opioid analgesics was started. Although buprenorphine hydrochloride patch was used to avoid high-dose oral treatment, severe cutaneous symptoms (dermatosis) developed, for which the opioid treatment was switched to tramadol/apap, initiated on an unspecified date.On an unspecified date thereafter, the pain was alleviated, and the symptoms were stabilized for approximately 3 months, but the treatment with tramadol/apap was interrupted (drug dose omission) at the patient's discretion on the day of her child's athletic meeting for fear of onset of sleepiness during the athletic meeting and as a result, she experienced withdrawal symptoms such as cold sweat and restlessness. The oral treatment with tramadol/apap was resumed after the athletic meeting had been completed, and the symptoms disappeared.No relevant laboratory data were reported.No treatment of the AEs was reported.The outcome of withdrawal syndrome was reported as recovered/resolved.No further information was available.Literature citation:takemura m. experience of two cases presenting with withdrawal signs due to interruption of oral treatment with weak opioid. 44th annual meeting of the japanese society for the study of chronic pain; feb-2015. abstract of congress. 2015;101***Third party case numbers:e2b company number: jp-jnjfoc-20150306405e2b report duplicate: 201504950</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment>Withdrawal syndrome is assessed as serious.Withdrawal syndrome is listed in the Company Core Data Sheet of tramadol hydrochloride, paracetamol (oral).Withdrawal syndrome is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol.Drug dose omission is not considered to be an adverse reaction, as only its possible consequences would be reactions. Therefore, seriousness, listedness, and causality are assessed to be not applicable.The information in this single case does not appear to alter the favorable benefit to risk ratio of tramadol hydrochloride, paracetamol.Time to onset is plausible, and withdrawal symptoms belong to the known reaction pattern for tramadol hydrochloride, paracetamol. Hence, withdrawal reaction is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol.The additionally reported events of cold sweat and restlessness were deleted, as they are considered to be symptoms of the diagnosed withdrawal syndrome.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-45</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150416</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150413</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150413</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist />
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb />
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-45</companynumb>
		<duplicate />
		<casenullification />
		<nullificationreason />
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>D</reportergivename>
			<reportermiddlename />
			<reporterfamilyname>Takeuchi</reporterfamilyname>
			<reporterorganization>4400771</reporterorganization>
			<reporterdepartment />
			<reporterstreet />
			<reportercity />
			<reporterstate />
			<reporterpostcode>914-0024</reporterpostcode>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Takeuchi D, et al. Clinical experience: Use of duloxetine in 2 patients with chronic pain. Japanese Journal of Psychiatric Treatment. 2015;30:415-419</literaturereference>
			<studyname />
			<sponsorstudynumb />
			<observestudytype />
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename />
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate />
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype />
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment />
			<receivertitle />
			<receivergivename />
			<receivermiddlename />
			<receiverfamilyname />
			<receiverstreetaddress />
			<receivercity />
			<receiverstate />
			<receiverpostcode />
			<receivercountrycode />
			<receivertel />
			<receivertelextension />
			<receivertelcountrycode />
			<receiverfax />
			<receiverfaxextension />
			<receiverfaxcountrycode />
			<receiveremailaddress />
		</receiver>
		<patient>
			<patientinitial />
			<patientgpmedicalrecordnumb />
			<patientspecialistrecordnumb />
			<patienthospitalrecordnumb />
			<patientinvestigationnumb />
			<patientbirthdateformat />
			<patientbirthdate />
			<patientonsetage>80</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod />
			<gestationperiodunit />
			<patientagegroup />
			<patientweight />
			<patientheight />
			<patientsex>2</patientsex>
			<lastmenstrualdateformat />
			<patientlastmenstrualdate />
			<patientmedicalhistorytext />
			<resultstestsprocedures>(In July of an unspecified year (1 year after the onset of right shoulder pain))Hamilton Rating Scale for Depression (HAM-D) score, 6; McGill Pain Questionnaire (MPQ) score, 32.(In the middle of August of an unspecified year (1 year after the onset of right shoulder pain))HAM-D score, 2; MPQ score, 9.(In the early December of an unspecified year (1 year after the onset of right shoulder pain))HAM-D score, 3; MPQ score, 21.(In February of an unspecified year (2 years after the onset of right shoulder pain)) (Two months after the drug was resumed)HAM-D score, 2; MPQ score, 11.</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10012378</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10040617</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10064332</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10054095</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10028836</patientepisodename>
				<patientmedicalstartdateformat />
				<patientmedicalstartdate />
				<patientmedicalcontinue />
				<patientmedicalenddateformat />
				<patientmedicalenddate />
				<patientmedicalcomment />
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Adverse event</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10021328</reactionmeddrallt>
				<reactionmeddraversionpt />
				<reactionmeddrapt />
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat />
				<reactionstartdate />
				<reactionenddateformat />
				<reactionenddate />
				<reactionduration />
				<reactiondurationunit />
				<reactionfirsttime />
				<reactionfirsttimeunit />
				<reactionlasttime />
				<reactionlasttimeunit />
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Paxil Tablet</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion />
				<drugindication />
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PAROXETINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021328</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021328</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>FELBINAC</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK mg, UNK</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>FELBINAC</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>LOXOPROFEN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>LOXOPROFEN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREGABALIN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ACETAMINOPHEN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DULOXETINE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>DULOXETINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DULOXETINE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb />
				<drugauthorizationnumb />
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder />
				<drugstructuredosagenumb />
				<drugstructuredosageunit />
				<drugseparatedosagenumb />
				<drugintervaldosageunitnumb />
				<drugintervaldosagedefinition />
				<drugcumulativedosagenumb />
				<drugcumulativedosageunit />
				<drugdosagetext />
				<drugdosageform />
				<drugadministrationroute />
				<drugparadministration />
				<reactiongestationperiod />
				<reactiongestationperiodunit />
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10016323</drugindication>
				<drugstartdateformat />
				<drugstartdate />
				<drugstartperiod />
				<drugstartperiodunit />
				<druglastperiod />
				<druglastperiodunit />
				<drugenddateformat />
				<drugenddate />
				<drugtreatmentduration />
				<drugtreatmentdurationunit />
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional />
				<activesubstance>
					<activesubstancename>DULOXETINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was reported in a literature article and described the occurrence of ileus in a 80-year-old female patient who received paroxetine hydrochloride (Paxil) tablet for an unknown indication. (Takeuchi D, et al.. Clinical experience: Use of duloxetine in 2 patients with chronic pain. Japanese Journal of Psychiatric Treatment 2015; 30: 415-419.)Co-suspect products included felbinac for pain, loxoprofen for pain, pregabalin for pain, paracetamol (Acetaminophen) for pain and duloxetine for pain and feeling anxious.Concurrent medical conditions included depression, shoulder pain, complex regional pain syndrome, neuropathic pain and neck pain.On an unknown date, the patient started Paxil at an unknown dose and frequency, felbinac 70 mg daily, loxoprofen 180 mg daily, pregabalin at an unknown dose and frequency, Acetaminophen 600 mg daily and duloxetine at an unknown dose and frequency. On an unknown date, unknown after starting Paxil, the patient experienced ileus (serious criteria GSK medically significant). Paxil was discontinued (Dechallenge was positive). Rechallenge with Paxil was unknown. Felbinac was discontinued (Dechallenge was positive). Rechallenge with felbinac was unknown. Loxoprofen was discontinued (Dechallenge was positive). Rechallenge with loxoprofen was unknown. Pregabalin was discontinued (Dechallenge was positive). Rechallenge with pregabalin was unknown. Acetaminophen was discontinued (Dechallenge was positive). Rechallenge with Acetaminophen was unknown. Duloxetine was discontinued (Dechallenge was positive). Rechallenge with duloxetine was unknown. On an unknown date, the outcome of the ileus was recovering/resolving.The reporter considered the ileus to be related to Paxil.On 26 July of an unspecified year (2 years before), the patient was diagnosed with depression.On 04 August of the same year, she was admitted to the reporter's hospital. She started receiving paroxetine, and remission of the depression was achieved approximately half a year later.However, her family members showed reluctance to take care of her at home and her hospitalization was prolonged.Subsequent course: Around September of an unspecified year, right shoulder pain developed triggered by pushing a handcart in the ward, and the pain was gradually aggravated.Radiography was performed in the reporter's hospital but no fractures were shown. Topical treatment with felbinac at 70 mg/day and oral treatment with loxoprofen at 180 mg/day were started for the pain, but the treatments were ineffective as expected.Blood count test, biochemical test, thyroid function test, electrocardiography, chest X-ray, head computerized tomography (CT) scan, and electroencephalography were performed as precautionary measures, but no abnormalities were observed in any of these examinations.She was referred to a physician of a pain clinic accordingly, and was diagnosed as having 'pain possibly similar to complex regional pain syndrome' and started to undergo periodic stellate ganglion blocks regularly.However, she stated that the pain abated a little immediately after the injections but returned as usual after a while.In around February of an unspecified year (1 year later), she started to complain of left posterior cervical pain. Possible relationship to neuropathic pain due to cervical spondylosis was indicated at the pain clinic, and she started taking pregabalin at 75 mg and acetaminophen at 600 mg/day in addition to the treatment with stellate ganglion blocks she had received.However, her pain did not improve much. The physician of the pain clinic asked the reporter's department to use an antidepressant drug. Her attending physician explained the patient and her family about the off-label use of duloxetine in expectation of improvement of the pain and anxiety as well as the risk of adverse reactions to duloxetine. They fully understood the explanation and consented to the treatment.Before the start of duloxetine, Hamilton Rating Scale for Depression (HAM-D) score was 6 and McGill Pain Questionnaire (MPQ) score was 32. In the early July of the same year, duloxetine at 20 mg/day was added, and the dose of the drug was escalated every 2 weeks to 60 mg/day. In the middle of August of the same year, she stated that her pain reduced by 90%.HAM-D and MPQ scores improved to 2 and 9, respectively. However, she had ileus in October of the same year and was transferred to Hospital B in the end of the same month. Drug-induced ileus was found at Hospital B, and all the drugs were discontinued.As the ileus improved by November of the same year, she was readmitted to the reporter's hospital. She had no mood disorder or chronic pain at that time.The patient did not meet the diagnostic criteria of major depression. However, considering the prolonged hospitalization and a history of depression, the possibility that she started to have depressive symptoms which had not meet diagnostic criteria of major depression yet before the start of duloxetine could not be ruled out.</narrativeincludeclinical>
				<reportercomment />
				<senderdiagnosismeddraversion />
				<senderdiagnosis />
				<sendercomment />
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
